Batch vs continuous vs cell-free biomanufacturing: throughput, cost, and quality compared

Why It Matters

The global biomanufacturing market reached $418 billion in 2025 and is projected to exceed $650 billion by 2030 (McKinsey, 2025). As demand for biologics, alternative proteins, and bio-based chemicals intensifies, the choice of production platform determines whether a company can hit cost targets, maintain product quality, and scale sustainably. Batch fermentation still accounts for roughly 70% of commercial bioprocessing capacity worldwide (BioPlan Associates, 2025), but continuous bioprocessing and cell-free synthesis are gaining ground rapidly. Continuous processes can cut per-unit production costs by 20 to 40% at scale, while cell-free platforms compress development timelines from months to days. For sustainability professionals evaluating biomanufacturing investments, understanding the throughput, cost, and quality trade-offs across these three paradigms is essential to making informed decisions about capital allocation, process design, and environmental performance.

Key Concepts

Batch fermentation is the traditional workhorse of bioprocessing. A bioreactor is charged with media and inoculated with cells; the process runs through growth, production, and harvest phases before the reactor is cleaned and re-charged. Each run is discrete, making quality control straightforward but limiting throughput to one cycle at a time.

Continuous bioprocessing keeps cells in a steady-state production mode by continuously feeding fresh media and withdrawing product. Perfusion bioreactors, tangential flow filtration, and continuous chromatography enable uninterrupted manufacturing. The FDA and EMA have actively encouraged adoption, with the FDA issuing updated guidance on continuous manufacturing validation in 2024 (FDA, 2024).

Cell-free synthesis removes the cell entirely. Lysates or purified enzyme systems catalyze biochemical reactions in vitro, enabling protein production, metabolic pathway prototyping, and small-molecule synthesis without the constraints of cell viability, growth dynamics, or genetic instability. The global cell-free protein expression market was valued at $310 million in 2025 and is growing at 12% annually (Grand View Research, 2025).

Key metrics for comparison include volumetric productivity (grams per liter per day), capital expenditure (CapEx), operating expenditure (OpEx) per gram of product, batch failure rate, product consistency (measured by critical quality attributes), and environmental footprint (water, energy, and waste per kilogram of output).

Head-to-Head Comparison

Continuous processes achieve 3 to 5 times higher volumetric productivity than batch systems largely because they eliminate downtime between runs and maintain cells at peak productivity (Konstantinov and Cooney, 2024). Cell-free systems, while lower in absolute output, excel where speed to product is critical: a new molecule can be prototyped and produced within days rather than the months required for cell line development.

Cost Analysis

Capital expenditure. A conventional 200,000-liter batch facility costs $200 to $500 million to build (BPOG, 2025). Continuous facilities operating at equivalent annual output can use reactors 10 to 50 times smaller, but require $10 to $50 million in additional investment for advanced automation, real-time analytics (PAT), and continuous downstream processing equipment. Total CapEx for a continuous facility typically runs $150 to $350 million for comparable output, a 15 to 30% reduction. Cell-free systems require minimal infrastructure: a well-equipped production lab can be established for $1 to $10 million, though per-gram reagent costs remain high.

Operating expenditure. Continuous processes reduce OpEx by 20 to 40% through lower media waste, reduced labor per unit, and higher equipment utilization (BioPlan Associates, 2025). A fed-batch monoclonal antibody process costs roughly $300 to $500 per gram at 10,000-liter scale; an equivalent perfusion process achieves $180 to $350 per gram. Cell-free synthesis currently costs $1,000 to $10,000 per gram, restricting economic viability to high-value molecules such as personalized medicines, diagnostic enzymes, and research-grade proteins.

Cost crossover points. For products with annual demand above 100 kilograms, continuous processes typically achieve lower total cost of ownership than batch within 3 to 5 years of operation. Cell-free becomes cost-competitive with batch only for products with annual volumes below 10 kilograms or market values exceeding $5,000 per gram (Swartz, 2025).

Use Cases and Best Fit

Batch fermentation remains optimal for:

• Established biologics with proven cell lines and regulatory filings (biosimilars, vaccines)
• Products where existing facility infrastructure is already amortized
• Organizations with limited process analytical technology capabilities
• Markets where regulatory agencies have not yet accepted continuous manufacturing dossiers

Continuous bioprocessing excels for:

• High-volume biologics such as monoclonal antibodies, where Roche and Samsung Biologics have deployed perfusion systems producing over 1,000 kg annually per facility (Roche, 2025)
• Products requiring tight quality control, such as cell and gene therapy intermediates
• Manufacturers seeking to reduce environmental footprint, as Sanofi reported a 35% reduction in water use and 28% reduction in energy consumption after transitioning its Framingham facility to continuous processing (Sanofi, 2025)
• New facility construction where greenfield design can incorporate continuous principles from the start

Cell-free synthesis is best suited for:

• Rapid prototyping and screening of enzyme variants or metabolic pathways
• Point-of-care manufacturing of diagnostic proteins or personalized therapies
• Toxic protein production that would kill living cells
• Emergency response biologics, as demonstrated by Tierra Biosciences and Nuclera, which produced candidate proteins within 48 hours during pandemic preparedness exercises (Tierra Biosciences, 2024)

Decision Framework

When selecting a bioprocessing platform, decision-makers should evaluate five dimensions:

1. Product volume and value. Map your product onto a volume-value matrix. Products exceeding 100 kg/year with moderate margins favor continuous. Products below 10 kg/year with very high value favor cell-free. Everything else defaults to batch unless other factors tip the balance.

2. Speed to market. If first-mover advantage is critical, cell-free can deliver initial product in weeks. Continuous platforms take longer to validate but offer faster campaign turnaround once operational. Batch occupies the middle ground.

3. Regulatory pathway. Consult your target regulatory agencies early. The FDA has approved continuous manufacturing for small molecules since 2015 and increasingly supports biologics applications. The EMA published its reflection paper on continuous manufacturing in 2024 (EMA, 2024). For markets in Asia-Pacific, regulatory acceptance varies and may favor batch-based filings.

4. Sustainability targets. If your organization has committed to science-based targets or water reduction goals, continuous processing offers measurable advantages. A lifecycle assessment by the BioPhorum Operations Group found that continuous processes generate 30 to 50% less waste per kilogram of active pharmaceutical ingredient compared to batch (BPOG, 2025).

5. Organizational readiness. Continuous processing demands higher operator skill levels, more sophisticated process analytical technology, and robust digital infrastructure. Assess your team's capabilities honestly before committing. Cell-free systems require synthetic biology expertise but minimal fermentation experience.

Key Players

Established Leaders

• Sartorius — Leading supplier of perfusion bioreactors and continuous downstream equipment, with over 4,000 bioprocess installations globally
• Cytiva (Danaher) — Provides end-to-end continuous bioprocessing solutions including FlexFactory modular facilities
• Merck KGaA (MilliporeSigma) — Offers BioContinuum platform integrating continuous upstream and downstream unit operations
• Samsung Biologics — World's largest contract biomanufacturer with 604,000 L capacity, actively deploying continuous perfusion lines
• Roche — Pioneer in continuous manufacturing for monoclonal antibodies at commercial scale

Emerging Startups

• Tierra Biosciences — Cell-free protein expression platform for rapid biologics prototyping, raised $20M Series A in 2024
• Nuclera — Desktop cell-free protein printing for on-demand biologics
• Synonym Bio — Building open-access biomanufacturing facilities optimized for continuous fermentation of bio-based materials
• Culture Biosciences — Cloud-connected bioreactor platform enabling parallel process optimization

Key Investors/Funders

• ARPA-H — Funding next-generation biomanufacturing platforms including cell-free and continuous systems for rapid pandemic response
• Breakthrough Energy Ventures — Investing in sustainable bioprocess companies including Synonym Bio
• BARDA — Supporting continuous manufacturing readiness for vaccine and therapeutic production

FAQ

Is continuous bioprocessing always cheaper than batch? Not always. Continuous processes deliver cost savings of 20 to 40% at scale, but the crossover point depends on production volume, product complexity, and facility age. For legacy products manufactured in fully depreciated batch facilities, switching to continuous may not be justified unless quality improvements or sustainability goals drive the decision.

Can cell-free systems produce at commercial scale? Currently, cell-free synthesis is limited to small-scale, high-value applications. The highest reported production volumes remain under 100 liters per run. However, advances in lysate preparation and energy regeneration systems are pushing cell-free toward kilogram-scale production of select molecules, with several companies targeting commercial launch before 2028 (Swartz, 2025).

What are the biggest barriers to adopting continuous bioprocessing? The top barriers include the high initial investment in process analytical technology and automation (typically $10 to $50 million above batch equivalents), limited regulatory precedent for biologic products, workforce retraining requirements, and the need to redesign downstream purification trains. Organizations that have invested in digital twins and advanced process control report smoother transitions (Konstantinov and Cooney, 2024).

How do environmental footprints compare across the three approaches? Continuous bioprocessing offers the most favorable environmental profile at commercial scale, with 30 to 50% less water consumption and waste generation compared to batch. Cell-free systems use the least energy and water per gram at small scale but become resource-intensive if scaled up due to costly reagent production. Batch remains the most resource-intensive per unit of output at equivalent scales (BPOG, 2025).

Which approach is best for alternative proteins and precision fermentation? For alternative proteins produced via precision fermentation, the answer depends on maturity. Early-stage companies benefit from batch systems to establish proof of concept. Companies scaling to commercial volumes, such as those targeting food-grade proteins at tens of thousands of kilograms per year, increasingly adopt continuous fermentation to reduce costs per kilogram to competitive levels. Cell-free is rarely used for bulk protein production due to cost constraints.

Sources

• McKinsey & Company. (2025). The Bio Revolution: Innovations Transforming Economies, Societies, and Our Lives. McKinsey Global Institute.
• BioPlan Associates. (2025). 22nd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. BioPlan Associates.
• Grand View Research. (2025). Cell-Free Protein Expression Market Size, Share & Trends Analysis Report. Grand View Research.
• Konstantinov, K. and Cooney, C. (2024). Continuous Bioprocessing: Economic and Quality Advantages at Commercial Scale. Trends in Biotechnology, 42(3), 215–228.
• BioPhorum Operations Group. (2025). Sustainability Benchmarking: Lifecycle Assessment of Batch vs. Continuous Biomanufacturing. BPOG.
• U.S. Food and Drug Administration. (2024). Guidance for Industry: Continuous Manufacturing of Biological Products. FDA.
• European Medicines Agency. (2024). Reflection Paper on the Use of Continuous Manufacturing for Biological Medicinal Products. EMA.
• Sanofi. (2025). Sustainability Report 2024: Continuous Manufacturing and Environmental Performance. Sanofi.
• Swartz, J. (2025). Cell-Free Biology: Engineering Beyond the Cell. Nature Biotechnology Reviews, 43(1), 45–59.
• Tierra Biosciences. (2024). Rapid Cell-Free Protein Production for Pandemic Preparedness. Tierra Biosciences Technical Report.